News | October 09, 2023
Mitsui invests in Lokavant Holdings
Lokavant provides clinical trial intelligence
Lokavant provides clinical trial intelligence
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products
The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Subscribe To Our Newsletter & Stay Updated
